FDA official logo
GSRS logo
PFDA official logo

NATALIZUMAB

  • UNII: 3JB47N2Q2P
  • Preferred Substance Name: NATALIZUMAB

  • 189261-10-7
  • AN100226M
  • ANTEGRAN
  • ANTEGREN
  • IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMER
  • IMMUNOGLOBULIN G4 (HUMAN-MOUSE MONOCLONAL AN100226 4-CHAIN ANTI-HUMAN INTEGRIN 4), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL AN100226 LIGHT CHAIN, DIMER
  • NATALIZUMAB [EMA EPAR]
  • NATALIZUMAB [INN]
  • NATALIZUMAB [JAN]
  • NATALIZUMAB [MART.]
  • NATALIZUMAB [MI]
  • NATALIZUMAB [PURPLE BOOK CDER]
  • NATALIZUMAB [USAN]
  • NATALIZUMAB [VANDF]
  • NATALIZUMAB [WHO-DD]
  • NATALIZUMAB ELAN PHARMA
  • TYSABRI

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.




About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

Powered by

DNAnexus official logo